This chart shows the generic firms that had the most successful drug patent challenges last year.
Companies that successfully challenge patents on branded drugs are granted six months of generic exclusivity. And, because
first-to-market generics tend to sell at 70% or more of the price of the branded drug, the financial rewards stemming from
the market exclusivity granted for drug patent challenges can more than cover the subtantial costs of drug patent challenge and associated litigation.
The most successful patent challengers in 2016 were
- Par Pharm Inc
- Actavis Labs Fl
- Mayne Pharma Inc
- Mayne Pharma
- Hetero Labs Ltd Iii
- Lupin Atlantis